HyperStealth Biotechnology Corporation

Cannabis Testing Services Market by Test Type, Product Type, End-users, and Region - Global Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022

The "Cannabis Testing Services Market, by Test Type, by Product Type, by End-users, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabis Testing Services Market, by Test Type, by Product Type, by End-users, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing adoption of inorganic growth strategies such as acquisition by key players is expected to drive the market growth over the forecast period.
  • For instance, in December 2021, Pfizer Inc., multinational pharmaceutical and Biotechnology Corporation had acquired with the clinical-stage company Arena Pharmaceuticals, a Biotech Company.
  • Furthermore, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation had signed agreement for testing analysis with the clinical-stage company Arena Pharmaceuticals for a total equity value of around $6.7 billion.

Minerva Biotechnologies Announces Opening 1st-In-Human Phase I/II Trial of a MUC1* Targeting CAR T for Metastatic Breast Cancers at City of Hope

Retrieved on: 
Tuesday, February 1, 2022

Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, California.

Key Points: 
  • Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, California.
  • This is a first-in-human trial targeting the tumor-associated form of MUC1, called MUC1* (muk 1 star).
  • MUC1* is the transmembrane cleavage product that is a growth factor receptor that drives growth of an estimated 93% of breast cancers.
  • NCT04020575 is a first-in-human trial of huMNC2-CAR44, an autologous CAR T therapy targeting MUC1* in metastatic breast cancer in patients with MUC1* reactive tumors.